IN2014DN06169A - - Google Patents

Info

Publication number
IN2014DN06169A
IN2014DN06169A IN6169DEN2014A IN2014DN06169A IN 2014DN06169 A IN2014DN06169 A IN 2014DN06169A IN 6169DEN2014 A IN6169DEN2014 A IN 6169DEN2014A IN 2014DN06169 A IN2014DN06169 A IN 2014DN06169A
Authority
IN
India
Prior art keywords
salts
compositions
methods
cyclic compounds
certain fused
Prior art date
Application number
Other languages
English (en)
Inventor
Changyou Zhou
Bo Ren
Hexiang Wang
Original Assignee
Beigene Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beigene Ltd filed Critical Beigene Ltd
Publication of IN2014DN06169A publication Critical patent/IN2014DN06169A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06Peri-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/55171,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/16Peri-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
IN6169DEN2014 2011-12-31 2011-12-31 IN2014DN06169A (enEXAMPLES)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2011/085148 WO2013097225A1 (en) 2011-12-31 2011-12-31 Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as parp inhibitors

Publications (1)

Publication Number Publication Date
IN2014DN06169A true IN2014DN06169A (enEXAMPLES) 2015-08-21

Family

ID=48696280

Family Applications (1)

Application Number Title Priority Date Filing Date
IN6169DEN2014 IN2014DN06169A (enEXAMPLES) 2011-12-31 2011-12-31

Country Status (29)

Country Link
US (4) US9260440B2 (enEXAMPLES)
EP (2) EP3315500B1 (enEXAMPLES)
JP (1) JP6034877B2 (enEXAMPLES)
KR (1) KR101716012B1 (enEXAMPLES)
CN (2) CN103703004B (enEXAMPLES)
AU (1) AU2011384858B2 (enEXAMPLES)
BR (1) BR112014012628B8 (enEXAMPLES)
CA (1) CA2856309C (enEXAMPLES)
CY (1) CY1119804T1 (enEXAMPLES)
DK (1) DK2797921T3 (enEXAMPLES)
EA (1) EA027533B1 (enEXAMPLES)
ES (1) ES2645814T3 (enEXAMPLES)
HR (1) HRP20171883T1 (enEXAMPLES)
HU (1) HUE035153T2 (enEXAMPLES)
IL (1) IL233365A (enEXAMPLES)
IN (1) IN2014DN06169A (enEXAMPLES)
LT (1) LT2797921T (enEXAMPLES)
ME (1) ME02855B (enEXAMPLES)
MX (1) MX353578B (enEXAMPLES)
NO (1) NO2797921T3 (enEXAMPLES)
NZ (1) NZ624063A (enEXAMPLES)
PL (1) PL2797921T3 (enEXAMPLES)
PT (1) PT2797921T (enEXAMPLES)
RS (1) RS56616B1 (enEXAMPLES)
SG (1) SG11201401726VA (enEXAMPLES)
SI (1) SI2797921T1 (enEXAMPLES)
SM (1) SMT201700543T1 (enEXAMPLES)
WO (1) WO2013097225A1 (enEXAMPLES)
ZA (1) ZA201405560B (enEXAMPLES)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2014DN06169A (enEXAMPLES) 2011-12-31 2015-08-21 Beigene Ltd
DK2822656T3 (en) 2012-03-07 2017-01-30 Inst Of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
EP3044221B1 (en) 2013-09-11 2018-02-21 Institute of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
BR112018003634B1 (pt) * 2015-08-25 2023-11-21 Beigene Switzerland Gmbh Forma cristalina de sesqui-hidrato de um inibidor parp, método de preparação da dita forma cristalina e composição farmacêutica compreendendo a dita forma
RU2738646C2 (ru) * 2016-04-01 2020-12-15 РЕКЬЮРИУМ АйПи ХОЛДИНГС, ЛЛС Модуляторы эстрогеновых рецепторов
TWI806840B (zh) * 2016-09-27 2023-07-01 英屬開曼群島商百濟神州有限公司 使用包含parp抑制劑的組合產品治療癌症
CN110392687B (zh) * 2017-02-28 2022-08-02 百济神州(苏州)生物科技有限公司 稠合的四环或五环二氢二氮杂䓬并咔唑酮的盐的结晶形式及其用途
CN106883232B (zh) * 2017-03-31 2019-01-22 苏州康润医药有限公司 一种氮杂非那烯-3-酮的衍生物及其制备方法与应用
AU2018302999A1 (en) * 2017-07-17 2020-01-30 Beigene, Ltd. Treatment cancers using a combination comprising PARP inhibitors, temozolomide and/or radiation therapy
US20210205323A1 (en) * 2018-06-01 2021-07-08 Beigene, Ltd. Maintenance therapy of a parp inhibitor in treating gastric cancer
CN111171031B (zh) * 2019-05-10 2021-04-09 百济神州(苏州)生物科技有限公司 一种含parp抑制剂倍半水合物产物的制备方法
CN111171002B (zh) * 2019-05-16 2021-04-06 百济神州(苏州)生物科技有限公司 一种parp抑制剂中间体的制备方法
TW202110455A (zh) * 2019-05-31 2021-03-16 英屬開曼群島商百濟神州有限公司 二磷酸腺苷核糖多聚酶抑制劑微丸組成物、其製備方法、口服製劑以及治療二磷酸腺苷核糖多聚酶相關疾病的方法
BR112022002138A2 (pt) 2019-08-06 2022-04-19 Recurium Ip Holdings Llc Moduladores do receptor de estrogênio para tratamento de mutantes
WO2021046014A1 (en) 2019-09-03 2021-03-11 Teva Czech Industries S.R.O Solid state forms of pamiparib and process for preparation thereof
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE445326B (sv) 1983-04-05 1986-06-16 Malmstroem Anders E H Sett och anordning for forhindrande av veggturbulens
US6799298B2 (en) 1998-03-11 2004-09-28 Overture Services, Inc. Technique for locating an item of interest within a stored representation of data
AU781711B2 (en) 1999-01-11 2005-06-09 Agouron Pharmaceuticals, Inc. Tricyclic inhibitors of poly(ADP-ribose) polymerases
EP1339402B1 (en) 2000-12-01 2010-08-25 Eisai Inc. Azaphenanthridone derivatives and their use as parp inhibitors
US6423705B1 (en) 2001-01-25 2002-07-23 Pfizer Inc. Combination therapy
US6906096B2 (en) 2002-06-28 2005-06-14 Irm Llc 4,7-Disubstituted indoles and methods of making
CN1759118B (zh) 2003-01-09 2010-12-08 美国辉瑞有限公司 作为激酶抑制剂的二氮杂*并吲哚衍生物
AU2004242947B2 (en) 2003-05-28 2010-04-29 Eisai Inc. Compounds, methods and pharmaceutical compositions for inhibiting PARP
WO2007113647A1 (en) 2006-04-04 2007-10-11 Pfizer Products Inc. Polymorphic forms of (2r,z)-2-amino-2-cyclohexyl-n-(5-(1-methyl-1h-pyrazol-4υl)-1-oxo-2,6-dihydro-1h-[1,2]diazepino[4,5,6-cd]indol-8-yl)acetamide
BRPI0709731A2 (pt) 2006-04-04 2011-07-26 Pfizer Prod Inc terapia de combinaÇço de (2r,z)-2-amino-2-cicloexil-n-(5-(1-metil-1h-pirazol-4-il)-1- oxo-2,6-diidro-1h-[1,2]diazepino[4,5,6-cd]indol-8-il)acet amida
MX2010005070A (es) 2007-11-15 2010-05-24 Angeletti P Ist Richerche Bio Derivados de piridazinona como inhibidores de parp.
ES2466565T3 (es) 2008-08-06 2014-06-10 Biomarin Pharmaceutical Inc. Inhibidores dihidropiridoftalazinona de poli(ADP-ribosa)polimerasa (PARP)
WO2011130661A1 (en) 2010-04-16 2011-10-20 Biomarin Pharmaceutical Inc. Methods of using dihydropyridophthalazinone inhibitors of poly (adp-ribose)polymerase (parp)
IN2014DN06169A (enEXAMPLES) 2011-12-31 2015-08-21 Beigene Ltd
ES2792183T3 (es) 2013-09-13 2020-11-10 Beigene Switzerland Gmbh Anticuerpos anti-PD1 y su uso como productos terapéuticos y de diagnóstico
TWI687438B (zh) 2014-07-03 2020-03-11 英屬開曼群島商百濟神州生物科技有限公司 抗pd-l1抗體及其作為治療及診斷之用途
US9637488B2 (en) 2015-01-29 2017-05-02 Fuqiang Ruan Heterocyclic compounds as inhibitors of class I PI3KS
BR112018003634B1 (pt) 2015-08-25 2023-11-21 Beigene Switzerland Gmbh Forma cristalina de sesqui-hidrato de um inibidor parp, método de preparação da dita forma cristalina e composição farmacêutica compreendendo a dita forma
TWI806840B (zh) 2016-09-27 2023-07-01 英屬開曼群島商百濟神州有限公司 使用包含parp抑制劑的組合產品治療癌症
CN110392687B (zh) 2017-02-28 2022-08-02 百济神州(苏州)生物科技有限公司 稠合的四环或五环二氢二氮杂䓬并咔唑酮的盐的结晶形式及其用途
AU2018302999A1 (en) 2017-07-17 2020-01-30 Beigene, Ltd. Treatment cancers using a combination comprising PARP inhibitors, temozolomide and/or radiation therapy

Also Published As

Publication number Publication date
EP2797921B1 (en) 2017-09-06
BR112014012628B1 (pt) 2021-02-09
US20170305921A1 (en) 2017-10-26
US20150175617A1 (en) 2015-06-25
SI2797921T1 (en) 2018-01-31
ES2645814T3 (es) 2017-12-07
US20160159811A1 (en) 2016-06-09
BR112014012628A2 (pt) 2017-06-13
MX353578B (es) 2018-01-19
JP6034877B2 (ja) 2016-11-30
EP2797921A1 (en) 2014-11-05
NZ624063A (en) 2016-09-30
SMT201700543T1 (it) 2018-01-11
HRP20171883T1 (hr) 2018-01-12
CN106220635B (zh) 2019-03-08
JP2015503526A (ja) 2015-02-02
CN103703004A (zh) 2014-04-02
CN103703004B (zh) 2016-06-29
US20190016731A1 (en) 2019-01-17
CA2856309A1 (en) 2013-07-04
ZA201405560B (en) 2017-02-22
PT2797921T (pt) 2017-11-14
LT2797921T (lt) 2017-11-27
CN106220635A (zh) 2016-12-14
US10112952B2 (en) 2018-10-30
ME02855B (me) 2018-04-20
MX2014007840A (es) 2014-08-21
WO2013097225A1 (en) 2013-07-04
EP3315500A1 (en) 2018-05-02
CY1119804T1 (el) 2018-06-27
RS56616B1 (sr) 2018-02-28
KR20140107353A (ko) 2014-09-04
EA201491303A1 (ru) 2014-10-30
EA027533B1 (ru) 2017-08-31
BR112014012628B8 (pt) 2023-01-17
US10501467B2 (en) 2019-12-10
KR101716012B1 (ko) 2017-03-13
NO2797921T3 (enEXAMPLES) 2018-02-03
DK2797921T3 (en) 2017-10-02
IL233365A (en) 2016-08-31
IL233365A0 (en) 2014-08-31
US9260440B2 (en) 2016-02-16
AU2011384858A1 (en) 2014-05-29
SG11201401726VA (en) 2014-10-30
EP3315500B1 (en) 2020-03-18
AU2011384858B2 (en) 2016-05-05
HK1192233A1 (zh) 2014-08-15
EP2797921A4 (en) 2015-10-21
CA2856309C (en) 2016-06-07
HUE035153T2 (en) 2018-05-02
PL2797921T3 (pl) 2018-02-28
US9617273B2 (en) 2017-04-11

Similar Documents

Publication Publication Date Title
IN2014DN06169A (enEXAMPLES)
IN2014DN06166A (enEXAMPLES)
IN2015DN00127A (enEXAMPLES)
UY33958A (es) Inhibidores de la glucosilceramida sintasa
CO7111289A2 (es) Compuestos inhibidores de metaloenzimas
UY34365A (es) Compuestos heterociclicos
IN2014CN02283A (enEXAMPLES)
UY33930A (es) Inhibidores novedosos de quinasas
UY34602A (es) ?Derivados de bencimidazolil- e imidazopiridinil-metilamina?
CR20140106A (es) Compuestos y composiciones como inhibidores de la quinasa c-kit
UY34836A (es) Nuevo organismos
IN2014MN02598A (enEXAMPLES)
IN2014CN02639A (enEXAMPLES)
IN2012DE02913A (enEXAMPLES)
CR20130539A (es) Triazolopiridinas
UY33977A (es) Híbrido de pigmento autoaglutinante.
BR112014003027A2 (pt) formulação herbicida melhorada
EP2825963A4 (en) ESTABLISHMENT OF EXECUTION TIME INSTRUMENTATION REPORTS
UY34158A (es) Composicion herbicida
CO7151478A2 (es) Formulaciones estabilizadas que contienen anticuerpos anti-dll4
BR112014027219A2 (pt) método
EP2739764A4 (en) ION SOURCE
IN2012DE02933A (enEXAMPLES)
AU2013347232A8 (en) 3-Aminocyclopentane carboxamide derivatives
BR112014002498A2 (pt) “composição de tratamento oral não aquosa”